Formosa Pharmaceuticals Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	12.16	143.36	31.17	1.32	28.53	-
Revenue Growth (YoY)	-91.15%	359.89%	2270.49%	-95.39%	-	-
Cost of Revenue	11.61	24.37	3.83	0.98	0.27	-
Gross Profit	0.55	118.99	27.35	0.33	28.26	-
Selling, General & Admin	47.68	60.8	40.2	25.53	20.65	17.31
Research & Development	112.39	226	270.18	356.47	387.62	216.29
Operating Expenses	167.88	294.62	310.38	382	408.27	233.6
Operating Income	-167.33	-175.63	-283.04	-381.67	-380.01	-233.6
Interest Expense	-0.48	-0.57	-4.31	-0.99	-2.21	-0.1
Interest & Investment Income	25.92	21.18	12.42	0.47	0.06	0.48
Currency Exchange Gain (Loss)	18.95	-18.62	9.29	-25.15	20.97	14.04
Other Non Operating Income (Expenses)	50.07	1.03	0.09	0.75	0.01	-0.25
EBT Excluding Unusual Items	-72.88	-172.61	-265.54	-406.59	-361.18	-219.43
Gain (Loss) on Sale of Assets	-	-	-	-	-0.2	-0.72
Other Unusual Items	-	-6.96	-34.53	-	-37.04	-
Pretax Income	-72.88	-179.57	-300.07	-406.59	-398.42	-220.15
Income Tax Expense	1.35	21.36	21.86	-0.42	2.4	-0.42
Earnings From Continuing Operations	-74.23	-200.93	-321.93	-406.17	-400.82	-219.73
Minority Interest in Earnings	-0.02	-0.08	-0.03	-0.1	-0.06	0.07
Net Income	-74.25	-201.01	-321.96	-406.27	-400.88	-219.66
Net Income to Common	-74.25	-201.01	-321.96	-406.27	-400.88	-219.66
Shares Outstanding (Basic)	149	141	124	105	92	71
Shares Outstanding (Diluted)	149	141	124	105	92	71
Shares Change (YoY)	7.04%	13.48%	18.00%	13.70%	31.19%	8.70%
EPS (Basic)	-0.50	-1.43	-2.59	-3.86	-4.33	-3.12
EPS (Diluted)	-0.50	-1.43	-2.59	-3.86	-4.33	-3.12
Free Cash Flow	-56.01	-135.95	-198.21	-346.15	-331.35	-180.4
Free Cash Flow Per Share	-0.38	-0.96	-1.60	-3.29	-3.58	-2.56
Gross Margin	4.52%	83.00%	87.73%	25.32%	99.06%	-
Operating Margin	-1375.65%	-122.51%	-907.98%	-29024.26%	-1332.01%	-
Profit Margin	-610.38%	-140.22%	-1032.84%	-30895.21%	-1405.18%	-
Free Cash Flow Margin	-460.47%	-94.83%	-635.85%	-26323.19%	-1161.46%	-
EBITDA	-127.61	-139.99	-247.53	-345.56	-345.41	-200.58
EBITDA Margin	-	-97.65%	-	-	-	-
D&A For EBITDA	39.72	35.64	35.51	36.11	34.6	33.02
EBIT	-167.33	-175.63	-283.04	-381.67	-380.01	-233.6
EBIT Margin	-	-122.51%	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.